Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAGITTARIUS
2023-509851-15-00Phase 3Authorised
- Sponsor
- IFOM
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of panitumumab, capecitabine, levoleucovorin, fluorouracil, nivolumab and 7 more in colon cancer (4 arms), sponsored by IFOM. Primary endpoint: 2-year recurrence-free survival in ctDNA-positive patients. Planned start May 2024; status: authorised.
02
Drugs
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2023-509851-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509851-15-00.